Literature DB >> 9134238

Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States.

E Kampman1, J D Potter, M L Slattery, B J Caan, S Edwards.   

Abstract

Hormonal factors have been inconsistently associated with colon cancer risk in women. The associations between reproductive events, menstrual factors, exogenous hormones, and colon cancer were evaluated in a large case-control study (894 female cases and 1,120 female age-matched population-based controls) in the United States, stratifying by age at diagnosis, tumor site, family history and other potential risk factors. Overall, higher parity was associated with a marginally decreased risk of colon cancer (five or more births compared with nulliparous: odds ratio [OR] = 0.75, 95 percent confidence interval [CI] = 0.53-1.06) after adjusting for age at diagnosis, family history of colorectal cancer, vigorous lifetime physical activity, body mass index (BMI) (wt/ht1.5), total energy intake, and aspirin use. No important associations were observed for other reproductive or menstrual events. An inverse association between recent use of hormone replacement therapy (HRT) and colon cancer was observed (OR = 0.71, CI = 0.56-0.89). Although interaction terms were not significant, this inverse association appeared to be more pronounced for those with an older age at diagnosis; for those without a first-degree relative with colorectal cancer; and for those with a relatively low BMI. The reduced risk associated with HRT use did not appear to be explained by other behaviors related to HRT use.

Entities:  

Mesh:

Year:  1997        PMID: 9134238     DOI: 10.1023/a:1018459911147

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  37 in total

1.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

2.  Dietary phytoestrogen intake is associated with reduced colorectal cancer risk.

Authors:  Michelle Cotterchio; Beatrice A Boucher; Michael Manno; Steven Gallinger; Allan Okey; Patricia Harper
Journal:  J Nutr       Date:  2006-12       Impact factor: 4.798

3.  Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.

Authors:  Hsi-Hsien Hsu; Sue-Fei Cheng; Li-Mien Chen; Jer-Yu Liu; Chun-Hsien Chu; Yi-Jiun Weng; Zih-Ying Li; Chung-Sheng Lin; Shin-Da Lee; Wei-Wen Kuo; Chih-Yang Huang
Journal:  Mol Cell Biochem       Date:  2006-04-21       Impact factor: 3.396

4.  Oral contraceptive use and colorectal cancer in the Nurses' Health Study I and II.

Authors:  Brittany M Charlton; Kana Wu; Xuehong Zhang; Edward L Giovannucci; Charles S Fuchs; Stacey A Missmer; Bernard Rosner; Susan E Hankinson; Walter C Willett; Karin B Michels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-10       Impact factor: 4.254

5.  Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.

Authors:  Martha L Slattery; Jennifer S Herrick; Abbie Lundgreen; Francis A Fitzpatrick; Karen Curtin; Roger K Wolff
Journal:  Carcinogenesis       Date:  2010-07-09       Impact factor: 4.944

6.  Estrogens, phytoestrogens and colorectal neoproliferative lesions.

Authors:  Michele Barone; Sabina Tanzi; Katia Lofano; Maria Principia Scavo; Raffaella Guido; Lucia Demarinis; Maria Beatrice Principi; Antongiulio Bucci; Alfredo Di Leo
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

7.  Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition.

Authors:  K K Tsilidis; N E Allen; T J Key; K Bakken; E Lund; F Berrino; A Fournier; A Olsen; A Tjønneland; K Overvad; M-C Boutron-Ruault; F Clavel-Chapelon; G Byrnes; V Chajes; S Rinaldi; J Chang-Claude; R Kaaks; M Bergmann; H Boeing; Y Koumantaki; G Stasinopoulou; A Trichopoulou; D Palli; G Tagliabue; S Panico; R Tumino; P Vineis; H B Bueno-de-Mesquita; F J B van Duijnhoven; C H van Gils; P H M Peeters; L Rodríguez; C A González; M-J Sánchez; M-D Chirlaque; A Barricarte; M Dorronsoro; S Borgquist; J Manjer; B van Guelpen; G Hallmans; S A Rodwell; K-T Khaw; T Norat; D Romaguera; E Riboli
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

8.  Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with better [corrected] prognosis.

Authors:  Vassiliki Tzelepi; Petros Grivas; Zinovia Kefalopoulou; Haralabos Kalofonos; John N Varakis; Georgia Sotiropoulou-Bonikou
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

9.  Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.

Authors:  Vassiliki Tzelepi; Petros Grivas; Zinovia Kefalopoulou; Haralabos Kalofonos; John N Varakis; Maria Melachrinou; Georgia Sotiropoulou-Bonikou
Journal:  Virchows Arch       Date:  2009-03-07       Impact factor: 4.064

10.  Pregnancy does not influence colonic polyp multiplicity but may modulate upper gastrointestinal disease in patients with FAP.

Authors:  Nirosha Suraweera; Andrew Latchford; Amy McCart; Pauline Rogers; Sarah Spain; Oliver Sieber; Robin Phillips; Ian Tomlinson; Andrew Silver
Journal:  J Med Genet       Date:  2007-05-11       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.